Clinical trial

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV…

NCT00252148 · International AIDS Vaccine Initiative, Other · Completed

Key facts

NCT number NCT00252148
Title Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
Official title Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of a Modified Vaccinia Ankara (MVA) Vectored HIV-1 (ADMVA) Vaccine Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers
Lead sponsor International AIDS Vaccine Initiative, Other
Collaborators Aaron Diamond AIDS Research Center University of Rochester
Status Completed
Phase Phase 1
Study type Interventional
Conditions HIV Infection
Intervention type Biological
Interventions ADMVA
Enrollment 48
Start date Jan 1, 2005
Primary completion Aug 1, 2007
Completion Aug 1, 2007
First posted Nov 11, 2005
Last update posted Feb 11, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies